Limited coverage criteria – rotigotine

Last updated on March 21, 2025

Special Authority requests can now be submitted online. It's simple and quick!

Generic name		rotigotine
Strength & form		2 mg/24h, 4 mg/24h, 6 mg/24h, 8 mg/24h transdermal patch

Special Authority criteria	Approval period
For the treatment of advanced-stage Parkinson’s disease, when the patient is receiving treatment with levodopa and requires additional adjunctive therapy	Indefinite

Practitioner exemptions

None

Special notes

PharmaCare does not provide coverage of rotigotine for restless leg syndrome.

Special Authority request form(s)

Log in to eForms
HLTH 5328 – General Special Authority request (PDF, 656KB)

Did you find what you were looking for?

The B.C. Public Service acknowledges the territories of First Nations around B.C. and is grateful to carry out our work on these lands. We acknowledge the rights, interests, priorities, and concerns of all Indigenous Peoples - First Nations, Métis, and Inuit - respecting and acknowledging their distinct cultures, histories, rights, laws, and governments.

More topics

Limited coverage criteria – rotigotine

Generic name

Strength & form

Special Authority criteria

Approval period

Practitioner exemptions

Special notes

Special Authority request form(s)